Peptides Are Everywhere. Businesses Are Cashing In.
Summary
This episode explores the booming peptide market, driven by social media hype and celebrity endorsements for unapproved injectables claiming to enhance health and appearance. With the FDA considering easing restrictions under Health Secretary RFK Jr., telehealth giants like Hims and Noom are positioning themselves to capitalize on the potential regulatory shift. The report highlights the risks of this gray market, including lack of safety data and potential side effects, as consumers increasingly trust influencers over traditional medical oversight.
Topics discussed
Introduction: The peptide craze and regulatory uncertainty
Show intro and sponsor advertisements
What are peptides and how the trend started
Risks, lack of data, and the gray market
RFK Jr.'s influence and push to loosen regulations
FDA committee vote to ease restrictions on six peptides
Telehealth giants Hims and Noom prepare for market
Smaller companies selling peptides despite regulatory limbo
Public trust in wellness influencers vs. medical regulation
Listen ad-free on Castria